Domestic and overseas marketing status tracking of Futibatinib

Futibatinib is a new type of targeted drug specifically designed to treat tumors caused by fibroblast growth factor receptor (FGFR) gene abnormalities. Since forbatinib was approved internationally, its market prospects have received widespread attention.

Overseas, forbatinib has received marketing approval in many countries and regions. In September 2022, the U.S. Food and Drug Administration (FDA) approved forbatinib for the first time to treat different types of intrahepatic cholangiocarcinoma. This approval marks a new stage in the application of forbatinib as an FGFR inhibitor in the treatment of intrahepatic cholangiocarcinoma. The US FDA's approval was based on its excellent performance in multiple clinical trials, especially its significant efficacy in patients with refractory intrahepatic cholangiocarcinoma. In addition, on July 4, 2023, the European Commission also conditionally approved forbatinib for the treatment of cholangiocarcinoma, which opened up new market space for its promotion in the European market.

In the Asian market, the original drug of forbatinib is produced by Otsuka Pharmaceutical (TAIHO ONCOLOGY) and has been approved in Japan and other regions. The Japanese version of the original drug of forbatinib is currently on the market in Japan and has received positive reviews from the market. In addition, generic versions of Lucius's version of forbatinib have also been launched in Laos and other regions. The Lucius version of the generic drug is basically the same as the original drug in terms of ingredients and mechanism of action, but it has certain advantages in price, so it provides more choices for some patients with poor economic conditions.

However, forbatinib has not yet been officially launched in China, nor has it been included in China's medical insurance coverage. This means that if Chinese patients need to use forbatinib, they may need to rely on imported drugs, which are more expensive. With the wide application of the drug around the world and the continuous verification of its efficacy, forbatinib is expected to be approved in the Chinese market and enter the medical insurance system in the future.

Reference materials:https://www.lytgobi.com/